
SCCO · NYSE
The supplied consensus is Sell across nine analysts, with targets ranging from $129.94 to $180.70 and averaging $177.50; the $50.76 spread puts the average close to the high end. The most bullish named target in the evidence is CICC’s $180.70, while Goldman Sachs’ $129 target is the lowest cited named target. Barclays is Underweight and cut its target to $165 from $168 on October 26. Other cited revisions include Goldman Sachs raising its target from $114.03 to $129 and Itaú BBA downgrading to Underperform, but their dates are not stated, so the evidence does not establish a broader revision direction over this week. The disagreement centers on growth potential versus project delays and cost pressure, alongside sharply different valuations.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Barclays | — | $165 | -7.1% | Oct 26, 2026 | Open the report this row came from | |
| CICC | — | $181 | +1.7% | Aug 21, 2026 | Open the report this row came from | |
| CICC | — | — | — | Jul 26, 2026 | Open the report this row came from | |
| CICC | — | — | — | Jul 25, 2026 | Open the report this row came from |